Clinical trial • Phase II • Oncology
Durvalumab for Non-small cell lung cancer
Phase II trial of Durvalumab for Non-small cell lung cancer. 130 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-small cell lung cancer
- Trial Stage
- Phase II
- Drug Modality
- Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 27-08-2024
- First CTIS Authorization Date
- 27-09-2024
Trial design
Phase II trial in Estonia, Lithuania, Finland and others.
- Target Sample Size
- 130
Recruitment
- Planned Sample Size
- 130
- Recruitment Window Months
- 175
Geography
- Total Number Of Sites
- 10
- Total Number Of Participants
- 130
Estonia
- Earliest CTIS Part Ii Submission Date
- 13-08-2024
- Latest Decision Or Authorization Date
- 27-09-2024
- Processing Time Days
- 45
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- North Estonia Medical Centre Foundation
- Department Name
- Department of chemotherapy, clinic of oncology and haematology
- Contact Person Name
- Kersti Oselin
- Contact Person Email
- kersti.oselin@regionaalhaigla.ee
Lithuania
- Earliest CTIS Part Ii Submission Date
- 13-08-2024
- Latest Decision Or Authorization Date
- 23-10-2024
- Processing Time Days
- 71
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Vilnius University Hospital
- Department Name
- Oncology Department
- Contact Person Name
- Saulius Cicenas
- Contact Person Email
- saulius.cicenas@nvi.lt
Finland
- Earliest CTIS Part Ii Submission Date
- 13-08-2024
- Latest Decision Or Authorization Date
- 27-09-2024
- Processing Time Days
- 45
- Number Of Sites
- 3
- Number Of Participants
- 15
Sites
- Site Name
- Turku University Hospital
- Department Name
- Oncology department
- Contact Person Name
- Maria Silvoniemi
- Contact Person Email
- maria.silvoniemi@varha.fi
- Site Name
- Oulu University Hospital
- Department Name
- department of oncology
- Contact Person Name
- Jussi Koivunen
- Contact Person Email
- jussi.koivunen@ppshp.fi
- Site Name
- Tampere University Hospital
- Department Name
- Department of oncology
- Contact Person Name
- Jarkko Ahvonen
- Contact Person Email
- jarkko.ahvonen@pshp.fi
Norway
- Earliest CTIS Part Ii Submission Date
- 13-08-2024
- Latest Decision Or Authorization Date
- 27-09-2024
- Processing Time Days
- 45
- Number Of Sites
- 5
- Number Of Participants
- 95
Sites
- Site Name
- Helse Bergen HF
- Department Name
- Avdeling for kreftbehandling og medisinsk fysikk
- Contact Person Name
- Marianne Aanerud
- Contact Person Email
- marianne.aanerud@helse-bergen.no
- Site Name
- University Hospital Of North Norway HF
- Department Name
- Department of oncology and Department of pulmology
- Contact Person Name
- Nina Helbekkmo
- Contact Person Email
- nina.helbekkmo@unn.no
- Site Name
- Stavanger University Hospital
- Department Name
- Department of pulmonary medicine
- Contact Person Name
- Tesfaye Madebo
- Contact Person Email
- tesfaye.madebo@sus.no
- Site Name
- Oslo University Hospital HF
- Department Name
- Department of oncology
- Contact Person Name
- Åslaug Helland
- Contact Person Email
- ahh@ous-hf.no
- Site Name
- St. Olavs Hospital HF
- Department Name
- Department of cancer research and molecular medicine
- Contact Person Name
- Bjørn Grønberg
- Contact Person Email
- bjorn.h.gronberg@gmail.com
Sponsor
Primary sponsor
- Full Name
- Oslo University Hospital Hf
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Norway
Investigational products
- Investigational Product Name
- Durvalumab (MEDI4736)
- Active Substance
- Durvalumab
- Modality
- Monoclonal antibody
Related trials
Other published trials that may interest you.